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Abstract
Purpose of review—The incidence of Alzheimer’s disease and related disorders is expected to 
triple by 2050. People with type 2 diabetes and prediabetes have a higher risk of cognitive 
dysfunction, including Alzheimer’s disease and vascular dementia. Controversy remains about 
when and how to prevent and treat cognitive dysfunction in people with or at high risk of diabetes.
Recent findings—In our review of ongoing clinical trials, we have found that there has been an 
increase in the number of studies assessing the efficacy of pharmacological and non-
pharmacological approaches to prevent or slow down cognitive impairment among people with or 
at high risk of diabetes.
Summary—Despite the considerable risk of cognitive impairment in people with diabetes and 
prediabetes, there is not enough evidence to support a specific treatment to prevent or slow mild 
cognitive impairment, or progression to Alzheimer’s disease or related disorders. Several ongoing 
trials are attempting to identify the usefulness of several compounds, as well as lifestyle changes 
including exercise and diet. Direct mechanisms linking diabetes to cognitive decline have not been 
elucidated.
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Introduction
The number of people worldwide living with dementia will double almost every 20 years, 
reaching 74.7 million in 2030 and 131.5 million in 2050 [1]. It is estimated that worldwide, 
approximately 2% (825,000) cases of Alzheimer’s disease (AD) – the main cause of age-
related dementia – are currently attributable to diabetes, including 3% (nearly 175,000) in 
the US [2]. Of considerable concern is the large and rapidly growing number of older adults 
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who have prediabetes, a metabolic condition associated with obesity that significantly 
increases the risk of developing type 2 diabetes [3]. In the U.S., for example, nearly 50% of 
adults have diabetes or pre-diabetes [4], suggesting that there is a substantial population that 
may have a dual risk of developing both diabetes and cognitive decline [5].
Evidence associating type 2 diabetes and severe cognitive decline emerged from 
epidemiological studies [6, 7]. The clinical and molecular determinants whereby diabetes 
increases the risk of cognitive impairment and AD remain to be elucidated. However, 
dysregulation of insulin might be directly linked to the increased vulnerability of people 
with or at high risk of type 2 diabetes. The role of insulin in the brain continues to be 
mysterious. Before the work of Chowers, Lavy and Halpern [8] demonstrated that insulin 
promoted the uptake of glucose by the brain, it was believed that the brain was insensitive to 
insulin. However, insulin receptors in the brain [9] were in fact found to be enriched in the 
olfactory areas and associated limbic regions[10], areas of pivotal importance for cognition 
and mood. Since then, the notion that insensitivity to insulin in the brain would lead to 
‘diabetes of the brain’ [11], which would manifest as cognitive dysfunction, has emerged. 
Epidemiological studies have shown that Alzheimer’s disease is exceedingly common 
among people suffering type 2 diabetes [16]. It has been reported that intranasal 
administration of insulin in small groups of adults with mild cognitive impairment (MCI) or 
AD has been associated with improvement of memory [12, 13], structural brain changes, and 
cerebral spinal fluid (CSF) [14] markers of AD pathology. Interestingly, this effect is more 
evident with short-term insulin and among individuals who do not carry allele 4 of the 
apolipoprotein E (APOE). In addition, administration of metformin – a medication that 
improves glucose control and helps reduce hyperinsulinemia – to a small group of elderly 
individuals who are overweight or obese (without treated diabetes) or who have MCI, over a 
period of 12 months, was associated with improvements in memory [15]. However, the 
prevention, prognosis, and management of cognitive decline associated with diabetes and 
prediabetes remain uncertain.
Cognitive Decline in Patients with or at High Risk of Diabetes
Cognitive performance in neuropsychological tests of Individuals with type 2 diabetes is 
lower than people of their same age, sex and education, across all ages and beginning in the 
very early stages of dysglicemia [17, 18]. Not all cognitive domains are affected equally: 
verbal memory, information processing speed, attention, and executive functioning are 
particularly affected [19]. The magnitude of these changes varies from subtle to mild 
cognitive impairment and dementia [20]. Determinants of the type of impairment, speed of 
decline, and progression to either Alzheimer’s disease or vascular dementia, are not known. 
In individuals with controlled type 2 diabetes, insulin-related variables (i.e. fasting insulin, 
C-peptide, and the Homeostasis Model Assessment of Insulin Resistance (HOMA2-IR)) are 
unrelated to the variance in cognitive performance, suggesting that peripheral insulin and 
cerebral insulin resistance might play different roles in cognition, at least among people with 
type 2 diabetes [21].
Insulin dysregulation may affect the brain beyond alterations in glucose metabolism. Insulin 
is a potent neuromodulator [22], able to potentiate the NMDA, AMPA, and GABA receptors 
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that are important mediators of synaptic plasticity [23]. Also, Insulin-receptors are 
preponderantly present in areas of the brain implicated in cognition [24], participating in 
several important processes underlying cognitive functioning, such as neuronal survival and 
firing [25]. However, the mechanisms that may be activated when there are peripheral – out 
of the brain – abnormalities of insulin levels remain unclear. Most of the available insulin in 
the brain is derived from circulating blood levels, and there is little de novo synthesis in the 
brain [26]. Insulin crosses the brain-blood barrier using active transporters that are saturable 
[27, 28], and the binding of insulin to the receptors can also be modulated by a wide array of 
factors, for example, as bacterial infections increase their uptake [29], while steroids 
decrease it [30]. In parallel with AD, reduced insulin sensitivity, as well as decreased density 
of insulin receptors in the brain, has been reported to be associated with increased 
accumulation of Aβ and tau protein hyperphosphorylation [31, 32].
In AD patients, the concentrations of insulin in the CSF are decreased, while they are raised 
in the blood plasma, and this is more evident in the advanced stages of AD and patients 
without APOE-4 allele [33]. Concurrently, there are other abnormalities that may or may not 
be related to cerebral insulin alterations. Several experimental pieces of evidence support the 
link between AD and type 2 diabetes through mitochondrial alterations and oxidative stress, 
altered energy and glucose metabolism, cholesterol modifications, and dysfunctional protein 
O-GlcNAcylation [22].
Alzheimer’s Disease Biomarkers in or at High Risk of Diabetes
Imaging and biomarker studies in humans are just beginning to provide insight into how 
diabetes and prediabetes may influence the progression of Alzheimer’s disease. Insulin 
resistance does not appear to influence CSF AD-related biomarkers (amyloid β-peptide 
(Aβ), total tau and tau phosphorylated at the Thr181 epitope) in cognitively healthy 
individuals [34]. However, in the same study, a significant relationship was reported between 
continuous values of plasma insulin and CSF Aβ/tau, driven by the correlation between 
insulin levels and levels of tau protein, and thus suggesting a link between insulin resistance 
and neuronal degeneration. This finding is not surprising, as studies in animal models have 
demonstrated an association between hyperinsulinemia and tau pathology [35]. Imaging 
studies assessing the accumulation of AD biomarkers in the brain tissue in humans are 
scarce. TAUPET is an ongoing study (NCT03024944) assessing whether diabetes status type 
2 diabetes and pre-diabetes, compared with normal glucose tolerance, is associated with 
increased tau accumulation in the brain of a community-based group of middle-aged 
Caribbean-Hispanics. Similar strategies will provide clarification as to the effect of insulin 
resistance in the progression of the neurodegenerative and vascular changes associated with 
AD.
Emerging Therapeutic Approaches
Advances in the knowledge of AD and type 2 diabetes have encouraged the development of 
treatments for preventing the pathogenic events that lead to severe cognitive impairment in 
individuals with prediabetes, metabolic syndrome or diabetes (Table 1), focused mainly on 
reducing brain insulin resistance. Clinical trials were identified using the public website 
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www.clinicaltrials.gov, which has tracked clinical trials since 2007. On May 1, 2017, there 
were twelve registered studies with the goal of either preventing the progression of MCI to 
AD, preventing MCI in people with or at high risk of type 2 diabetes and nine of them were 
ongoing. The studies are being carried out in four countries, and only two of them have 
concluded at the time of writing this review.
Glucagon-Like Peptide 1 (GLP1)
Glucagon-like peptide 1 (GLP1) agonists have been shown to offer neuroprotection [36], 
reverse brain insulin resistance [37, 38], reduce amyloid-β peptide accumulation and 
cytotoxicity [39], and decrease tau hyper-phosphorylation [40] in cellular and animal models 
of AD. Exenatide is one of the GLP-1 agonists that has been shown to decrease insulin 
resistance in the brain [37] and has already demonstrated clinical effectiveness to improve 
cognitive performance in patients with Parkinson’s disease [41]. The purpose of the clinical 
trial using Exetanide NCT01255163 was to prevent/slow the progression of cognitive 
dysfunction and related biomarkers in dysglycemic/prediabetic patients with MCI. The 
intervention consisted of subcutaneous injections of 2 mg long-acting exenatide once 
weekly.
Acetylcholinesterase inhibitors (AChEI)
The most widely used drugs for the symptomatic treatment of AD in clinical practice are 
AChEI. Besides its cholinergic effect, Galantamine has significant antiinflammatory effects 
[42], suppressing serum TNF and IL-6 levels, and decreasing body weight and abdominal 
adiposity and alleviating insulin resistance and fatty liver in mice with high-fat diet–induced 
obesity [43]. In AD, there is a significant state of neuroinflammation that contributes to the 
neurodegenerative process, especially the activated microglia [44]. The clinical trial 
NCT02283242 was established with the purpose of investigating the effects of Galantamine 
on inflammatory markers, as well as on abdominal visceral and epicardial fat and oxidative 
stress in patients with metabolic syndrome. The intervention consisted of the oral use of 
Galantamine for 12 weeks (8 mg for four weeks and 16 mg for eight weeks).
Vitamin D3 - Cholecalciferol
Meta-analyses of cross-sectional studies have reported impaired cognitive function among 
individuals with insufficient levels of Vitamin D [45], while analyses of longitudinal studies 
revealed a nearly two-fold risk of incident cognitive impairment [46] and a 20% increased 
risk of developing AD [47]. However, clinical interventional studies have failed to show that 
supplementation with Vitamin D improves cognitive outcomes in individuals [48]. The 
purposes of the clinical trial NCT02416193 were to determine (1) the effect of vitamin D3 
supplementation on cognitive function and (2) the effect of vitamin D3 supplementation on 
diabetes self-management in participants with type 2 diabetes who have symptoms of 
cognitive impairment but are not demented.
Resveratrol
Resveratrol is a potent caloric restriction-mimetic, able to penetrate the brain-blood barrier 
and showing positive influence on human cerebral blood flow [49], glucose control [50] and 
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verbal episodic memory performance [51]. It is found in grapes, red wine, peanuts and 
certain berries. The vast majority of studies dealing with the biological activity of resveratrol 
have been carried out in vitro and, to a lesser extent, in animal models [52]. Relatively few 
human clinical trials have been performed so far, and the main obstacle to translating the 
output of in vitro studies using resveratrol on humans relies on rapid metabolization, and 
consequentially, low bioavailability of the molecule [53].
Not only is there no clear dose-response concerning consumption of resveratrol and its 
metabolites, but in the brain, the availability or lack thereof of any of these metabolites is 
even lower than in blood [53]. Furthermore, the dose required to maximize effects without 
safety concerns is not yet known, and it is uncertain whether chronic ingestion of low 
resveratrol doses can exert more benefits than short-time exposures to high resveratrol doses 
[52].
In animal models, resveratrol influences the levels of several inflammatory response markers 
found to be elevated in diabetes, and other chronic disorders [54–56]. In humans, conflicting 
results [57, 58] and the lack of confirmation of several mechanisms involved in its activity in 
‘preclinical’ models [52] preclude its current pharmacological use in patients with or at high 
risk of diabetes, or at high risk for development of cognitive impairment. However, recent 
clinical trials support the notion that resveratrol is capable of increasing cerebral blood flow 
during task performance [59, 49, 60] and enhancing oxygen extraction [49], reducing 
glycated hemoglobin A1c, preserving hippocampus volume, and improving hippocampus 
resting state functional connectivity in at-risk patients for dementia [61]. A randomized, 
double-blind clinical trial phase 1 (NCT02502253) will evaluate the effects of a Bioactive 
Dietary Polyphenol Preparation (BDPP), a combination of two nutraceutical preparations 
(grape seed polyphenolic extract, and resveratrol) in mood and cognition of patients with 
MCI and prediabetes or type 2 diabetes.
Improved Control of Vascular Risk Factors
A growing body of evidence indicates that potentially modi able cardiovascular risk factors 
may play an important role in the high prevalence of AD, as well as in type 2 diabetes [62]. 
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability 
(FINGER) [63] – a 2 year multidomain intervention of diet, exercise, cognitive training, and 
vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people 
– found that there were significant intervention effects on the primary outcome (overall 
cognition), main cognitive secondary outcomes (executive functioning and processing 
speed), and other secondary outcomes (body mass index, dietary habits, and physical 
activity). However, it has not been clearly determined whether these vascular factors also 
affect AD progression itself and thus whether controlling vascular conditions can slow this 
progression [64]. Some studies show that there is a lower conversion rate from MCI to 
dementia, and lower progression of AD in patients in whom all vascular risk factors were 
treated compared to those in whom only some of the risk factors were treated [65, 66]. 
However other studies show no clinical impact [67] or improvement of cognition in 
overweight or obese patients with type 2 diabetes [68].
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The COVARAD is an ongoing clinical trial (NCT01423396) that compares the effect of 
“optimal” vs. “standard” care of hypertension, diabetes and dyslipidemia in AD patients, 
with the underlying hypothesis that those with stricter control of the risk factors will exhibit 
a slower cognitive decline. The BFIT is another clinical trial (NCT03117829) that compares 
cerebral blood flow, cognitive measures, and metabolomics markers in 40 sedentary 
(exercise <1 hour/week) participants who are 45–65 years of age, have impaired fasting 
glucose and are cognitively normal, and that undergo a 12-week diet and exercise 
intervention.
Dietary Pattern
Changes to diet have been recognized as a promising target for prevention of cognitive 
decline and AD [69, 70]. However, the optimal diet necessary to prevent the development of 
Alzheimer’s disease and the progression of cognitive decline has yet to be identified, 
particularly when the exposure to nutritional patterns has occurred for several decades and 
the individual may already be suffering from obesity, dyslipidemia, and/or diabetes. It is less 
problematic to study naturally occurring dietary patterns that are associated with fewer of 
these consequences, including dementia. Indeed, this approach has allowed the identification 
of the Mediterranean dietary pattern has been linked most consistently to lower Alzheimer’s 
disease incidence [71], and a Japanese pattern consisting of a high intake of fish, fruits and 
vegetables, potatoes, mushrooms, seaweeds, pickles, and soybeans that were also related to a 
lower risk of dementia [72]. At the same time, adverse dietary patterns have been identified. 
For example, a pro-inflammatory dietary pattern characterized by higher intake of red meat, 
processed meat, peas and legumes, and fried food, and lower intake of whole grains was 
found to be associated with higher inflammatory markers and accelerated cognitive decline 
at older ages [73]. The ongoing BEAM study (NCT02984540) compares the effects of a 
low-carbohydrate diet and a low fat diet for adults with mild memory loss and adults with 
pre-diabetes. The data collected will help determine changes in cognitive function, brain 
structure and function, and levels of certain proteins and hormones in body fluids.
Diets containing a preponderance of low-glycemic index food, i.e. containing carbohydrates 
leading to a slower release of glucose (e.g., rye bread) [74], low in saturated fats [75] and 
low in sodium [76], have been found to be associated with less cognitive impairment in old 
age. However, there is little consensus about recommendations, because of conflicting 
results and lack of randomized control trials. The MEAL-2 study (NCT02463084) was 
designed to compare the effects of a one-month diet high in saturated fat, glycemic index, 
and salt, to a diet low in these nutritional parameters on memory and other cognitive 
functions, magnetic resonance imaging measures of brain structure, function, and perfusion, 
as well as on blood and cerebrospinal fluid levels of amyloid-beta (Aβ), insulin, lipids 
cytokines, apolipoprotein E, apolipoprotein J, cortisol, soluble low density lipoprotein 
receptor-related protein, and glucose, in middle-aged adults (45–65 years of age) with 
normal cognition or mild cognitive impairment and prediabetes.
Meal frequency and timing, and calorie content of the diet have been suggested as potential 
modulators and influencers of disease trajectory during lifecourse [77, 78]. Diets that 
include calorie restriction and fasting have been associated with improved cognitive 
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performance, but few randomized clinical trials have been performed. A randomized 
controlled trial (NCT02460783) was established to test the effect of calorie restriction – 
defined as 500–600 calories a day for two consecutive days, followed by non-restricted 
eating for 5 days (5–2 CR) – on memory and executive function, resting state default mode 
network activity, brain metabolism, and AD biomarkers, in overweight to obese women and 
men (between 55 and 70 years of age.
Conclusions
Evidence suggests that patients with type 2 diabetes are at an increased risk of developing 
AD and that insulin resistance can lead to cognitive impairment [16, 79] Because both 
conditions are increasing exponentially, and only palliative treatments exist; new therapeutic 
targets for prevention, treatment and reversal of the decline in cognition are needed urgently. 
Intensive research efforts in preclinical models have provided numerous hypotheses about 
the interaction between insulin resistance and neurodegeneration through a plethora of 
pathways. There is not enough evidence to provide specific recommendations to prevent the 
cognitive decline in individuals with or at high risk of type 2 diabetes [80].
Approximately 60% of elderly adults with diabetes have at least one comorbid chronic 
disease [81], and as many as 40% of them have four or more comorbid diseases [82]. Early 
diagnosis of cognitive impairment and the identification of the subset of patients at a higher 
risk of developing AD is a challenge for healthcare providers. Most of the diabetes care 
guidelines typically focus on decreasing diabetes-related microvascular and cardiovascular 
complications, as well the prevention of hypoglycemia, as strategies to account for cognitive 
dysfunction in the tailoring of glycemic therapy, and do not suggest specific diets, exercise 
routines, or pharmacological agents [83]. Several ongoing trials are attempting to identify 
the usefulness of several compounds, as well as lifestyle changes including exercise and diet.
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Aβ Amyloid β-peptide
AChEI Acetylcholinesterase inhibitors
AD Alzheimer’s Disease
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
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BDPP Bioactive Dietary Polyphenol Preparation
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CSF Cerebral Spinal Fluid
GABA gamma-aminobutyric acid
GLP1 Glucagon-Like Peptide 1
HOMA2-IR Homeostasis Model Assessment of Insulin Resistance
IL-6 Interleukine 6
MCI Mild Cognitive Impairment
NMDA N-methyl-D-aspartate
TNF Tumor Necrosis Factor
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